ADARx is a clinical stage biotechnology company committed to turning cutting-edge science into life-saving therapeutics.
ADARx's vision is to provide effective and safe therapeutics to patients who suffer from intractable diseases.
ADARx was founded in 2019 by Zhen Li. The company is headquartered in San Diego, California.
ADARx has developed proprietary RNA delivery platforms and technology for silencing or editing target mRNA. Its proprietary RNA targeting platform, includes oligonucleotides for inhibition, degradation, and editing, together with novel oligonucleotide delivery technologies.
ADARx has a growing pipeline of RNA targeting therapeutics for treating diseases across a range of therapeutic areas including genetic, cardiometabolic, complement-mediated and central nervous system diseases.
ADARx currently havs 9 active programs in development. The company's lead product candidate, ADX-324, which is entering IND-enabling toxicology studies. ADARx's platform allows reproducibility and consistency with multiple mechanisms and a wide range of indications.
ADARx is backed by Bain Capital Life Sciences, TCGX, Blackrock, SR One Capital Management, OrbiMed, Lilly Asia Ventures, Cormorant Asset Managemen, Commodore Capital, Sirona Capital, Ascenta Capital, HBM Healthcare Investments, Invus, Marshall Wace, Redmile Group, and others. The company $200M in an oversubscribed $200M Series C round on Aug 09, 2023. This brings ADARx's total funding to $332M to date.